Clinical characteristics of and factors related to relapse in chronic hepatitis B patients after nucleoside analogues withdrawal / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 825-828, 2013.
Article
Dans Zh
| WPRIM
| ID: wpr-277989
Responsable en Bibliothèque :
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the clinical characteristics of and factors related to relapse in chronic hepatitis B (CHB) patients who had previously achieved cessation criteria and had been withdrawn from nucleoside analogues treatment.</p><p><b>METHODS</b>Sixty CHB patients who experienced relapse after nucleoside analogues withdrawal based on cessation criteria were enrolled in the study retrospectively. Each patient's data on biochemical, serological and viral characteristics corresponding to baseline (treatment initiation), withdrawal and relapse were collected. COX proportional hazard modeling was used to evaluate the factors related to relapse.</p><p><b>RESULTS</b>The hepatitis B e antigen (HBeAg)-positive and -negative patients had similar median antiviral treatment times (38 months (range 24 - 80) vs. 35 months (30 - 60); Z = -1.313, P more than 0.05). For all patients, the median follow-up time was 12 months (2 - 72), during which 49 (81.7%) patients developed virological breakthrough and 17 (28.3%) developed HBeAg recurrence. The patients who experienced virological breakthrough or HBeAg recurrence had significantly higher baseline levels of HBV DNA than those patients who remained disease-free (t = 2.15 and -2.54 respectively; P less than 0.05). The median relapse time of the HBeAg-positive patients was significantly longer than that of the HBeAg-negative patients (14 months (3 - 72) vs. 6 months (3 - 36); Chi-square test = 7.045, P less than 0.01). HBeAg status at baseline was identified as an independent factor associated with relapse (relative risk = 1.937, 95% confidence interval = 1.14-3.28, P less than 0.05).</p><p><b>CONCLUSION</b>HBeAg-positive and-negative patients showed distinct clinical characteristics of relapse, with the latter being more prone to relapse soon after nucleoside analogues withdrawal. Prolonging the treatment course may be beneficial to HBeAg-negative patients, even if cessation criteria are achieved.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Antiviraux
/
Récidive
/
Sang
/
ADN viral
/
Études rétrospectives
/
Résultat thérapeutique
/
Hépatite B chronique
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Antigènes e du virus de l'hépatite virale B
Type d'étude:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Limites du sujet:
Adult
/
Female
/
Humans
/
Male
langue:
Zh
Texte intégral:
Chinese Journal of Hepatology
Année:
2013
Type:
Article